TABLE 3.

NNRTI susceptibility of clinical HIV-1 isolates

HIV-1 strain (case no.)	Mean EC50 (μM) ±SD (fold resistance)a
	EFV	NVP	ETV
Wild type (V106 V179)	0.002 ± 0.0001	0.05 ± 0.004	0.0013 ± 0.0001
V106 V179 isolate (1)	0.002 ± 0.0004 (1.0)	0.04 ± 0.004 (0.8)	0.002 ± 0.0004 (1.5)
V106 V179 isolate (2)	0.002 ± 0.0003 (1.0)	0.04 ± 0.004 (0.8)	0.003 ± 0.0002 (2.3)
V106I V179 isolate (3)	0.002 ± 0.0002 (1.0)	0.03 ± 0.01 (0.6)	0.0012 ± 0.0002 (0.9)
V106I V179 isolate (4)	0.004 ± 0.001 (2.0)	0.09 ± 0.01 (1.8)	0.0024 ± 0.0002 (1.8)
V106 V179D isolate (5)	0.006 ± 0.001 (3.0)	0.07 ± 0.02 (1.4)	0.0015 ± 0.0002 (1.2)
V106 V179D isolate (6)	0.004 ± 0.002 (2.0)	0.07 ± 0.004 (1.4)	0.0011 ± 0.0001 (0.8)
V106I V179D isolate (7)	0.01 ± 0.001 (7.0)	0.19 ± 0.02 (3.8)	0.002 ± 0.0003 (1.5)

^aThe drug susceptibility assay was performed in triplicate and repeated three times (nine experiments). Data are means of nine experiments.